Pharmaceuticals

Cell and Gene Therapy Forecast Report – Designed for Decision Makers and Product Teams

July 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Growth Rate of the Cell and Gene Therapy Market?#_x000D_

The market size for cell and gene therapy has witnessed massive expansion in the past few years. It is projected to escalate from $12.01 billion in 2024 to $15.48 billion in 2025, with a compound annual growth rate (CAGR) of 28.9%. This growth during the historical period can be ascribed to the surge in investments towards cell and gene therapies, advancements in the research and development sector, progress in cancer drug discovery, an increase in public-private collaborations, robust economic development in emerging markets, enhanced healthcare spending and an upsurge in expenditure dedicated to pharmaceutical R&D._x000D_

_x000D_

#What Growth Rate Is Forecasted for the Cell and Gene Therapy Market by 2029?#_x000D_

The dimension of the cell and gene therapy market is set to witness impressive expansion in the upcoming years, ballooning up to $29.15 billion in 2029, demonstrating an annual compound growth rate of 17.1%. Factors contributing to growth during the forecast period include the growing instances of chronic diseases and prevailing cancer, an increase in the elderly population, and a heightened interest in cell and gene therapies, as well as escalated spending in healthcare. Key trends projected for the period of forecast include prioritization of advanced treatments such as chimeric antigen receptor (CAR) T-cell, substantial investment in research and securing funding, implementing strategic partnerships to incorporate state-of-the-art technologies, focusing on the construction of gene or genome editing tools, especially CRISPR, merger or acquisition of competitor firms, stepping up the volume of studies in the pipeline to create novel cell and gene therapies, and putting funds into the extension of manufacturing facilities._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp_x000D_

_x000D_

#Which Key Companies Are Shaping the Future of the Cell and Gene Therapy Market?#_x000D_

Major companies operating in the cell and gene therapy market include Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Biocon, Cipla, Stempeutics Research Pvt. Ltd., EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Oxford Biomedica plc, Santen Pharmaceutical Co., Therapeutic Innovation Australia, Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, inStem, Lonza, Nikon CeLL innovation Co. Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Oxford BioTherapeutics, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca_x000D_

_x000D_

#Which Factors Are Driving Demand in the Cell and Gene Therapy Industry?#_x000D_

The cell and gene therapy (CGT) market has experienced significant growth due to consistent investments and consolidation within the cell and gene therapy fields. Recognizing the potential of the CGT market, 80% of the top 20 biopharmaceutical companies in terms of revenue have added CGT products to their portfolio. Specifically, in 2023, the BioIndustry Association (BIA), a UK-based life sciences and biotech industry representative body, reported that UK cell and gene therapy companies claimed more than half of the venture capital funding gained by European firms. Typically, the UK accounts for approximately a third of all European venture capital investments in the life sciences sector, which emphasizes the strength of their cell and gene therapy sector. Constant investment and consolidation in CGT production have resulted in increased production capacity and market growth. For instance, in October 2024, Purespring Therapeutics, a UK-based biotech firm, secured $105 million in funding to back the development of gene therapies for kidney diseases, including a phase 1/2 trial of an experimental treatment for immunoglobulin A nephropathy (IgAN). Purespring uses adeno-associated viruses (AAVs) to administer its gene therapies._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=3472&type=smp_x000D_

_x000D_

#How Is the Cell and Gene Therapy Market Segmented by Several Divisions?#_x000D_

The cell and gene therapy market covered in this report is segmented –_x000D_

_x000D_

1) By Product: Cell Therapy, Gene Therapy_x000D_

2) By Application: Oncology, Neurological Disorders, Other Applications_x000D_

3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy_x000D_

2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy_x000D_

_x000D_

#What are the Emerging Market Trends Driving the Growth of the Cell and Gene Therapy Industry?#_x000D_

The cell and gene therapy (CGT) market is being significantly influenced by the rise of Chimeric antigen receptor (CAR) T-cell therapy. This therapy involves a combination of cell and gene therapy, where specialized T cells are gathered from the patient’s blood, and then genetically tinkered to generate modified receptors on their surfaces, recognized as chimeric antigen receptors (CARs). These altered T cells, equipped with particular constructs (receptors), are reintroduced into the patient. Subsequently, these re-engineered receptors on the T cells facilitate the targeting of the cancer cell’s surface antigen, culminating in the elimination of tumorous cells in the affected patients. As an example, in June 2022, the US-based pharmaceutical firm, Bristol-Myers Squibb Company, successfully gained approval from the United States Food and Drug Administration (US FDA) for their CAR T cell therapy named Breyanzi. This therapy is intended for treating adult patients suffering from large B-cell lymphoma (LBCL), which includes conditions like diffuse large B-cell lymphoma. Breyanzi is a distinct CAR T cell therapy, created from a patient’s own T cells, which are harvested and genetically reprogrammed into CAR T cells, then reintroduced into the patient through infusion as a one-time treatment._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report_x000D_

_x000D_

#Which Regions Are Driving Growth in the Cell and Gene Therapy Market?#_x000D_

North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3472_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the cell and gene therapy market, and how is it changing globally?_x000D_

2. Who are the major companies in the cell and gene therapy market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the cell and gene therapy market right now?_x000D_

4. Which products or customer segments are growing the most in the cell and gene therapy market?_x000D_

5. What factors are helping or slowing down the growth of the cell and gene therapy market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_